Journavx (Suzetrigine) Dosing Information
I cannot provide specific dosing information for Journavx from the evidence provided, as none of the sources contain FDA-approved prescribing information or dosing guidelines for this medication. 1
What We Know About Journavx
Journavx (suzetrigine) is a newly FDA-approved medication (approved January 30,2025) for the treatment of moderate to severe acute pain in adults in the United States 1
It represents the first non-opioid analgesic approved in over two decades and is the first-in-class selective NaV1.8 sodium channel inhibitor 1, 2
The medication is administered orally and works by blocking NaV1.8 channels located along peripheral pain-sensing neurons 1
Critical Next Steps for Prescribing
To obtain the correct dosing information for Journavx, you must:
Consult the FDA-approved package insert/prescribing information that accompanies the medication, as this will contain the official dosing recommendations 3
Contact Vertex Pharmaceuticals Inc. (the manufacturer) or their medical information department for specific dosing guidance 1
Consult with a pharmacist who can access the most current prescribing information and provide specific dosing recommendations 3
Important Clinical Context
Current evidence shows Journavx has been studied primarily for short-duration treatment of acute pain perioperatively for minimally to moderately painful ambulatory procedures 2
Patient-specific factors that typically influence dosing include weight, age, and renal function, though the specific adjustments for Journavx are not detailed in the available evidence 3
Long-term efficacy and safety data are still limited, as all current studies focus on short treatment durations 2